Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers

Histopathology
Ashwini RaghavendraSunil R Lakhani

Abstract

A better understanding of the expression of cancer/testis antigens (CTAs) in breast cancer might enable the identification of new immunotherapy options, especially for triple-negative (TN) tumours, which lack expression of the conventional therapeutic targets oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. The aim of this study was to quantify the expression of MAGE-A and NY-ESO-1 CTAs in breast cancer, and relate this to known clinicopathological parameters. We surveyed MAGE-A and NY-ESO-1 expression in an unselected cohort of 367 breast tumours (of which 65 were TN), with accompanying clinical follow-up data, by using immunohistochemical analysis of tissue microarrays. Relevant to their potential as vaccine targets in breast cancer, MAGE-A was expressed in 13% of cases, and NY-ESO-1 in 3.8%, with the majority of tumours showing fairly homogeneous staining within individual tissue cores (~85% of cases with staining in >75% of tumour cells). Most NY-ESO-1-positive cases also expressed MAGE-A (P = 2.06 × 10-9 ), and both were strongly associated with the TN phenotype (P < 0.0001), with the most proliferative and poorly differentiated cases, in paticular, showing genomic instability. This ...Continue Reading

References

Feb 21, 1996·Journal of the National Cancer Institute·S SjögrenJ Bergh
Apr 10, 1997·Nature·C LengauerB Vogelstein
Jan 1, 1999·Nature·C LengauerB Vogelstein
Sep 30, 1999·International Journal of Cancer. Journal International Du Cancer·E JägerA Knuth
Nov 26, 2002·Immunological Reviews·Matthew J ScanlanYao-Tseng Chen
Mar 18, 2004·Cancer Research·Yurika SugitaMorito Monden
Aug 12, 2005·International Journal of Cancer. Journal International Du Cancer·Axel MischoMichael Pfreundschuh
Nov 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ali O GureNasser K Altorki
Feb 13, 2007·International Journal of Cancer. Journal International Du Cancer·Jean-Philippe TheurillatHolger Moch
Mar 24, 2007·Nature Reviews. Molecular Cell Biology·Karen H Vousden, David P Lane
Jan 2, 2008·American Journal of Obstetrics and Gynecology·Chiara NapoletanoPierluigi Benedetti Panici
Aug 5, 2009·Proceedings of the National Academy of Sciences of the United States of America·Anita GrigoriadisA Munro Neville
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jul 9, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CuriglianoA Goldhirsch
Mar 23, 2011·Archives of Otolaryngology--head & Neck Surgery·Chad A GlazerJoseph A Califano
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Apr 3, 2012·The Journal of Clinical Investigation·Samuel F Bakhoum, Duane A Compton
Nov 7, 2012·Current Opinion in Cell Biology·Benjamin D Vitre, Don W Cleveland
Mar 27, 2013·The New England Journal of Medicine·Stephan A GruppCarl H June
May 2, 2013·Therapeutic Advances in Medical Oncology·John Stagg, Bertrand Allard
Feb 21, 2014·Science Translational Medicine·Marco L DavilaRenier Brentjens
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvia AdamsSunil S Badve
Sep 10, 2014·Proceedings of the National Academy of Sciences of the United States of America·Floris FoijerPeter K Sorger
Sep 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew D BursteinPowel H Brown
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Dec 17, 2014·Current Pharmaceutical Design·Ping YangQuansheng Zhou
Mar 31, 2015·Nature Communications·Simon JunankarAlexander Swarbrick
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Oct 31, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sherene LoiJustin M Balko

❮ Previous
Next ❯

Citations

Oct 24, 2018·The Journal of Pathology·Amy Ellen McCart ReedSunil R Lakhani
Sep 25, 2018·The Journal of Pathology. Clinical Research·Jamie R KutasovicPeter T Simpson
Sep 14, 2019·Oncology Letters·Binghan JiaYuemei Yang
Oct 6, 2020·Therapeutic Advances in Medical Oncology·Priyakshi Kalita-de CroftJodi M Saunus
Jul 20, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Yinxing ZhuWenwen Zhang
Aug 28, 2021·Cancers·Pere Llinàs-AriasDiego M Marzese

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Clinical Trials Mentioned

NCT02111850

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Cornelia LiedtkeLajos Pusztai
Asian Pacific Journal of Cancer Prevention : APJCP
Idil Cetin, Mehmet Topcul
© 2022 Meta ULC. All rights reserved